DPIs

Broad Range of DPI Technologies: Aptar Pharma offers a range of Dry Powder Inhaler (DPI) technologies for the treatment of chronic respiratory conditions.

Orbital™ is Aptar Pharma’s advanced DPI technology, a novel, easy to use device that delivers high payload powder drug formulations directly to the lungs. It’s a single use or reusable, adaptable, hand-held dry powder inhaler that provides many advantages over nebulizer or powder capsule drug delivery methods for a growing range of molecules.

Prohaler® is a high performance, multi-dose dry powder inhaler (DPI) device that helps to improve patient adherence in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its lightweight and intuitive design is easy to use and suitable for all patient types.

Nasal Drug Delivery

Broad Range of OINDP Devices and Integrated Development Services: Aptar Pharma offers a full range of Orally Inhaled and Nasal Drug Product (OINDP) drug delivery devices and advanced integrated development services for intranasal drug delivery including device manufacture, formulation development, and nasal cast tests through to clinical and commercial product manufacturing.

Aptar Pharma’s Unidose and Bidose nasal spray devices can reliably deliver precise nasal drug dosing in a simple, easy to use, safe, and portable way for both systemic and local administration with rapid onset capabilities. Ideal for new drug formulations as well as for drug repositioning and life-cycle management strategies, nasal drug delivery routes can offer differentiated products with enhanced patient benefits.

Drug Repositioning

Aptar Pharma is a leading global expert in repositioning existing drug products to nasal spray or nasal powder formulations in their proprietary nasal delivery systems. Nasal drug repositioning is a convenient and non invasive drug delivery route that has several medical and business advantages such as life cycle management opportunities, speed to market, ease of use and patient convenience and compliance.

Aptar Pharma’s nasal delivery devices meet the requirements of reliability, rapid onset, simplicity of use, portability and convenience that are required for delivering emergency or crisis medications making treatment more accessible in emergency situations outside of a medical setting.

Aptar Digital Health

Aptar Digital Health, a division of Aptar Pharma, offers a broad range of innovative and industry leading digital health solutions, including digital therapeutics, connected devices and disease management platforms, leveraging a holistic ecosystem of digital interventions.

Our digital healthcare solutions are patient-friendly, easy and intuitive to use and available as fully integrated technologies or extensions.

Aptar Pharma Services

Aptar Pharma offers a range of specialist analytical, laboratory and regulatory services to add value at every stage of the drug development process. These can accelerate and de-risk your drug development program along the way and we offer end-to-end support at every stage of your drug development journey.

Our broad range of services for respiratory drug development are offered by the Aptar Pharma companies Nanopharm, Next Breath and Noble.

Nanopharm is a world-leading specialist contract research organization (CRO) offering product design and development services for orally inhaled and nasal drug products (OINDPs).

Next Breath is a full-service cGMP-compliant laboratory specializing in analytical testing of various drug delivery systems from early stage to commercialization

Noble is a global leader in developing and commercializing adherence programs, medical device training solutions, robust patient onboarding strategies and multisensory products for the world’s top pharma brands and biotech companies.

pMDIs

Broad Range of Inhalation Drug Delivery Technologies and Services: With our broad range of drug delivery systems and services, Aptar Pharma’s inhalation drug delivery device technologies underpin some of the most successful commercially approved asthma and COPD therapeutics on the market. Our range includes Pressurized Metered Dose Inhalers (pMDIs), Breath Actuated Inhalers (BAIs), Dry Powder Inhalers (DPIs), as well as innovative drug delivery solutions like PureHale®, a ready-to-use, nebulizer-like device.

We are also supporting clients to transition away from traditional HFA propellants in their pMDIs and move towards newer propellant options with a lower Global Warming Potential (GWP) such as HFO1234ze and HFA P152a.